OncoMatch/Clinical Trials/NCT02343042
Selinexor and Backbone Treatments of Multiple Myeloma Patients
Is NCT02343042 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1/2 trial studies multiple treatments for multiple myeloma.
Treatment: Selinexor · Dexamethasone · Lenalidomide · Pomalidomide · Bortezomib · Daratumumab · Carfilzomib · Ixazomib · Elotuzumab · Clarithromycin · Belantamab Mafodotin · Mezigdomide — This study will independently assess the efficacy and safety of 11 combination therapies in 12 arms, in dose-escalation/-evaluation and expansion phases, for the treatment of patients with relapsed/refractory multiple myeloma (RRMM) and newly diagnosed multiple myeloma (NDMM). The combinations to be evaluated are: * Arm 1: Selinexor + dexamethasone + pomalidomide (SPd); enrollment complete * Arm 2: Selinexor + dexamethasone + bortezomib (SVd); enrollment complete * Arm 3: Selinexor + dexamethasone + lenalidomide (SRd) in RRMM; enrollment complete * Arm 4: Selinexor + dexamethasone + pomalidomide + bortezomib (SPVd); enrollment complete * Arm 5: Selinexor + dexamethasone + daratumumab (SDd); enrollment complete * Arm 6: Selinexor + dexamethasone + carfilzomib (SKd); enrollment complete * Arm 7: Selinexor + dexamethasone + lenalidomide (SRd) in NDMM; enrollment complete * Arm 8: Selinexor + dexamethasone + ixazomib (SNd); enrollment complete * Arm 9: Selinexor + dexamethasone + pomalidomide + elotuzumab (SPEd); enrollment complete * Arm 10: Selinexor + dexamethasone + belantamab mafodotin (SBd); enrollment complete * Arm 11: Selinexor + dexamethasone + pomalidomide + daratumumab (SDPd); enrollment complete * Arm 12: Selinexor + dexamethasone + mezigdomide (SMd); actively recruiting Selinexor pharmacokinetics: * PK Run-in (Days 1-14): Starting in protocol version 8.0, patients enrolled to any arm in the Dose Escalation Phase (i.e., Arm 4 \[SPVd\], Arm 6 \[SKd\], Arm 8 \[SNd\], Arm 9 \[SPEd\], Arm 10 \[SBd\], and Arm 11 \[SDPd\]) will also first be enrolled to a pharmacokinetics (PK) Run-in period until 9 patients have been enrolled to this period to evaluate the PK of selinexor before and after co-administration with a strong CYP3A4 inhibitor. This run-in period does not apply to Arm 12 (SMd).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Endocrine / hormonal
Other
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: selective inhibitor of nuclear export (sine) compound (selinexor)
Lab requirements
Blood counts
ANC ≥ 1,000/mm^3, hemoglobin ≥ 8.0 g/dL, platelet count ≥ 100,000/mm^3 (with arm-specific exceptions).
Kidney function
Estimated creatinine clearance (CrCl) thresholds vary by arm; see protocol for details.
Liver function
Total bilirubin and AST/ALT thresholds vary by arm; see protocol for details.
Cardiac function
No symptomatic ischemia, uncontrolled conduction abnormalities, CHF NYHA Class ≥ 3, MI within 3 months, or EF < 50% (Arms 1-11 only).
Adequate hepatic, renal, and hematopoietic function within 28 days prior to C1D1; cardiac function as specified.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Banner MD Anderson Cancer Center · Gilbert, Arizona
- Jonnsson Comprehensive Cancer Center / University of Los Angeles · Los Angeles, California
- Sarah Cannon-Colorado Blood Cancer Institute · Denver, Colorado
- Massachusetts General Hospital · Boston, Massachusetts
- Dana Farber Cancer Institute · Boston, Massachusetts
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT02343042 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior selective inhibitor of nuclear export (sine) compound disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages